Antithrombin III: Nursing Guide
Antithrombin III activity measures a liver-produced natural anticoagulant that inhibits thrombin and factor Xa — central to thrombophilia screening, unexplained venous thrombosis, and heparin-resistance evaluation. Nurses protect result validity with correct citrate collection, timing after acute clots and anticoagulants, and escalation when low activity conflicts with active thrombosis signs.
Contents
Quick Facts
Key Takeaway
Low antithrombin activity raises thrombosis risk but does not diagnose a clot by itself — and acute thrombosis, heparin, liver disease, DIC, and pregnancy can temporarily lower levels.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Light blue top
3.2% sodium citrate (9:1 blood-to-anticoagulant ratio)
Platelet-poor plasma (citrated)
Tube filled to completion per coagulation protocol; ~1 mL platelet-poor plasma after processing — follow laboratory minimum volume
Preferably several weeks after acute thrombosis is treated; not while on heparin or for at least 6 weeks after anticoagulants per clinical laboratory references; follow local thrombophilia-testing policy
No test preparation is usually required
Double-centrifuge to platelet-poor plasma, aliquot to plastic vial, freeze per institutional coagulation handling — not routine room-temperature transport
Typically days (referral coagulation laboratory)
Coagulation / specialized hemostasis laboratory
What is Antithrombin III?
Antithrombin III is a laboratory measurement of antithrombin functional activity in plasma (often reported as a percentage of normal). Antithrombin is a natural anticoagulant synthesized by the liver; it neutralizes activated coagulation factors, especially thrombin and factor Xa, and is the primary mediator of unfractionated heparin’s anticoagulant effect.
Overview
Nurses most often support antithrombin testing during thrombophilia panels after unexplained deep vein thrombosis, pulmonary embolism, unusual-site venous thrombosis, or strong family history of high-risk thrombophilia. Activity assay is the usual first-line test; if activity is low, antigen testing helps distinguish Type I (low quantity) from Type II (dysfunctional protein).
Because antithrombin is consumed during acute thrombosis and influenced by heparin, direct oral anticoagulants, liver disease, nephrotic syndrome, DIC, and pregnancy, results must be interpreted with timing and medication history. Repeat testing after recovery and off interfering anticoagulants is commonly required before labeling a lifelong hereditary deficiency.
Before collection, confirm the indication matches thrombophilia or heparin-resistance protocol, verify the patient is not actively clotting on heparin-contaminated lines, use a completely filled citrate tube with gentle mixing, and document recent VTE, anticoagulants, pregnancy, and liver or kidney disease. Escalate new or worsening leg swelling, chest pain, or shortness of breath according to facility policy — do not wait for the send-out result.
Antithrombin Testing Timing and Anticoagulation Safety
Antithrombin results guide long-term thrombosis risk decisions, but a low value during acute illness or incorrect specimen handling can mislabel a patient with hereditary deficiency. Never delay assessment of new leg swelling, chest pain, or dyspnoea while waiting for send-out coagulation results.
- Acute VTE symptoms with pending or low antithrombin — escalate clinically first
- Testing during acute clot, heparin therapy, or underfilled citrate tube without repeat plan
- Interpreting a single low activity as confirmed lifelong deficiency without antigen testing and repeat sampling
- Heparin resistance with therapeutic heparin — requires urgent haematology and dosing review
Document: indication and timing criteria met, tube fill and processing, anticoagulant holds, clinical VTE symptoms, result with reference interval, notifications, and repeat or genetics plan.
What Antithrombin III Can and Cannot Tell You
This test can help identify:
- Reduced functional antithrombin suggesting Type I or II deficiency when appropriately timed
- Acquired antithrombin consumption in DIC, liver disease, nephrotic syndrome, or recent thrombosis
- Contributing cause of heparin resistance or unusually high heparin requirements
- Need for antigen testing, repeat sampling, or genetics after a confirmed low activity
This test cannot:
- Diagnose acute deep vein thrombosis or pulmonary embolism by itself — use acute VTE pathways
- Replace clinical assessment, imaging, or D-dimer protocols where indicated
- Confirm hereditary deficiency from one sample during acute illness or on anticoagulants
- Determine anticoagulation duration alone — requires guideline-based specialist decisions
Timing and Anticoagulant Holds Before ATIII Draw
Verify
Clarify before proceeding when:
- Order is routine on acute admission without thrombophilia timing criteria
- Patient still on heparin or DOAC without authorized hold window
- Prior specimen rejected for underfill, hemolysis, or clot
- Active unilateral leg swelling, chest pain, or dyspnoea is present
- Central line draw may contain heparin flush and policy requires peripheral draw
- Result conflicts with strong family history but sample timing was during acute DVT only
- Laboratory requests repeat because of processing delay beyond stability window
Type I vs Type II Deficiency and Heparin Response
Pair antithrombin activity with timing after VTE, anticoagulant holds, antigen results, protein C and S, lupus anticoagulant, factor V Leiden where ordered, pregnancy plans, and current symptoms. Repeat testing after more than four weeks off interfering drugs is commonly required per ISTH guidance.
| Clinical context | Pair with antithrombin | Nursing focus |
|---|---|---|
| Post-VTE thrombophilia screen | Low activity + low antigen → Type I pattern | Support genetics referral and family screening per haematology |
| Low activity, normal antigen | Suggests Type II dysfunctional protein | Do not reassure based on activity alone; confirm with specialist interpretation |
| Active nephrotic syndrome | Low activity from loss — acquired | Document renal diagnosis; repeat after treatment when ordered |
| Heparin infusion subtherapeutic aPTT | Low antithrombin possible | Escalate to prescriber/haematology; do not independently increase heparin |
Antithrombin Results at the Bedside
| Bedside point | Nursing note |
|---|---|
| Timing trap | Drawing during acute DVT or on heparin commonly lowers activity — schedule per thrombophilia protocol |
| Tube fill | Underfilled citrate is a frequent reject — fill to the line and mix gently ×6 |
| Line draws | Heparin flush can invalidate the sample — confirm clean peripheral draw when required |
| Not a stat VTE test | Send-out antithrombin does not rule in or out PE today — escalate symptoms clinically |
| Confirm before labeling | One low result needs antigen and repeat off anticoagulants — avoid telling patients they have a “clot gene” prematurely |
| Heparin link | Teach that antithrombin is the cofactor for heparin — low levels may affect dosing under specialist care |
Thrombophilia Workup Workflow Integration
Diagnostic safety badge: Routine diagnostic test — standard identification, preparation, and result-follow-up checks still apply; low results may require confirmatory testing and specialist follow-up.
Check-before-test protocol
- Identity + indication + thrombophilia timing criteria
- Anticoagulant hold authorized and documented
- Citrated tube supply and processing steps confirmed
- Clinical VTE symptom screen
- Requisition clinical history completed
Critical teach-back questions
- “Can you tell me why we are checking your antithrombin level now rather than during your hospital clot treatment?”
- “What new leg or chest symptoms should you report before the result comes back?”
- “Why might the team repeat this blood test in several weeks?”
Care coordination: prescriber, haematology, laboratory/coagulation services, genetics service when indicated, anticoagulation clinic, and rapid response per institutional protocol.
Antithrombin Testing Quick Checklist
- Is this the right time after VTE treatment and anticoagulant hold?
- Was the citrate tube filled completely and processed per coagulation policy?
- Does the patient have any acute VTE symptoms needing escalation now?
- Will a low activity be confirmed with antigen and repeat testing?
- Who must be notified about an abnormal or critical result?
Why Antithrombin III is Ordered
Antithrombin testing is ordered when clinicians need to evaluate inherited or acquired antithrombin deficiency as part of a hypercoagulability workup, not as a routine screen for every patient with one clot.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Recurrent or unexplained venous thromboembolism | Is a high-risk thrombophilia such as antithrombin deficiency present? | Part of thrombophilia screening after appropriately timed sampling; antithrombin deficiency carries high VTE risk among inherited thrombophilias per reviewed references. |
| Family history of antithrombin, protein C, or protein S deficiency | Does this patient carry a high-risk familial thrombophilia? | ASH 2023 conditionally supports testing relatives when results may change prophylaxis or hormone-therapy decisions. |
| Suspected heparin resistance | Is antithrombin low despite adequate heparin dosing? | Heparin depends on antithrombin as cofactor; inherited deficiency can require unusually high heparin doses and specialist input per clinical laboratory references. |
| Unusual-site venous thrombosis (e.g., cerebral, splanchnic, renal) | Should long-term management consider severe thrombophilia? | Selected guideline scenarios support thrombophilia evaluation when results may influence duration of anticoagulation or prophylaxis decisions. |
Contraindications and Precautions
There is no single absolute laboratory contraindication, but nurses and collectors must not proceed with routine thrombophilia sampling when timing or specimen integrity would produce misleading results.
- Active acute thrombosis or recent VTE treatment without protocol delay — antithrombin may be consumptively low.
- Ongoing heparin therapy, heparin-contaminated line draw, or recent DOAC/heparin without hold per laboratory policy.
- Underfilled citrate tube, hemolyzed sample, or failure to obtain platelet-poor plasma.
- Liver disease, nephrotic syndrome, DIC, sepsis, surgery, and pregnancy may cause acquired deficiency patterns.
- Oral anticoagulants and some direct thrombin inhibitors may interfere with chromogenic activity assays per ISTH laboratory guidance.
- A single borderline low value should prompt repeat testing after recovery, not immediate lifelong diagnosis without confirmation.
- New or worsening unilateral leg swelling, pain, warmth, or redness while awaiting results.
- Acute chest pain, dyspnoea, tachycardia, or hypoxia suggesting pulmonary embolism.
- Confirmed very low antithrombin with active thrombosis signs — notify prescriber and haematology per protocol; evaluate outcomes of anticoagulation plan.
Patient Preparation
clinical laboratory references states no special patient preparation is required for antithrombin testing, but thrombophilia protocols usually require specific timing relative to acute clots and anticoagulants.
Pre-test checksReview unfractionated heparin, low-molecular-weight heparin, warfarin, direct oral anticoagulants, argatroban, bivalirudin, and oestrogen-containing contraceptives or HRT. Do not stop prescribed anticoagulation without prescriber authorization — clarify hold timing with the ordering clinician and laboratory.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Antithrombin III. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
Antithrombin activity is commonly reported as a percentage of the laboratory reference population. Decreased activity suggests deficiency; normal activity makes hereditary deficiency unlikely per clinical laboratory references. Antigen testing and repeat sampling clarify Type I vs Type II.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Within expected range or therapeutic target | Within institutional reference interval (activity %) | Functional antithrombin adequate at time of sample | If part of thrombophilia panel, interpret with other results; hereditary deficiency unlikely if activity normal |
| Near therapeutic target / borderline | Borderline low or discordant activity vs antigen | May reflect assay variation, pre-analytic error, or evolving acquired state | Recommend repeat testing per haematology protocol after appropriate interval and medication review |
| Prolonged / above target | Elevated antithrombin activity | Not usually clinically significant; may be seen with cholestasis, transplant, vitamin K deficiency, or warfarin per clinical laboratory references | Interpret with clinical context; not a typical thrombosis escalation trigger alone |
| Shortened / below target | Below reference interval (decreased activity) | Possible Type I or II deficiency, acquired consumption, or interfering anticoagulant/medication effect | Notify prescriber; arrange antigen assay and repeat testing off anticoagulants per protocol; genetics referral if confirmed |
Protocol targets, critical results and escalation
Universal numeric critical values for antithrombin are Turnaround and screening rules vary by institution; follow local institutional policy. Escalation is driven by clinical thrombosis risk, confirmed severe deficiency with symptoms, and heparin resistance requiring urgent haematology input.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Low antithrombin with acute VTE signs | Decreased activity plus new leg swelling, chest pain, or dyspnoea | Escalate according to facility policy; initiate acute VTE pathway per prescriber — do not delay for send-out results |
| Confirmed hereditary deficiency on heparin | Therapeutic heparin not achieving expected anticoagulation | Notify prescriber and haematology; antithrombin concentrate may be considered per specialist protocol |
| Specimen rejected / invalid | Hemolysis, clot, underfill, or heparin contamination | Repeat collection per coagulation policy before thrombophilia conclusions are made |
Stop routine workflow and escalate according to facility policy when the patient develops symptoms suggesting acute venous thromboembolism, when a critically low result is reported with haemodynamic compromise, or when results conflict strongly with the clinical picture.
Factors Affecting Results
Antithrombin assays are sensitive to pre-analytic variables and concurrent illness. Nurses prevent misinterpretation by correct citrate technique and documenting clinical context.
- Falsely low activity during acute thrombosis, surgery, or DIC consumption
- Heparin in sample or heparinized line causing assay interference
- Underfilled citrate tube altering anticoagulant ratio
- Falsely normal or elevated activity on some DOACs masking deficiency per ISTH guidance
- Single test during intercurrent illness without repeat confirmation
- Assuming normal activity rules out all thrombophilia — other defects may coexist
- Timing relative to acute VTE and anticoagulant therapy
- Liver disease, nephrotic syndrome, pregnancy, asparaginase chemotherapy
- Specimen quality — hemolysis, platelets, delayed processing
Antithrombin testing alone does not diagnose active thrombosis and cannot replace clinical probability assessment. ASH 2023 generally recommends against broad thrombophilia testing in many VTE scenarios; nurses support appropriate ordering and timing rather than routine panels on every clot. Reference ranges, critical thresholds, and repeat intervals vary by laboratory and method.
Nursing Responsibilities
Nursing responsibilities emphasize correct coagulation specimen handling, medication and timing documentation, symptomatic monitoring while results are pending, and clear communication of low or unexpected values.
Before the TestDocumentation
Documentation should link specimen quality, clinical context, and communication of abnormal results.
“Antithrombin activity specimen collected 09:40 — light-blue citrate tube filled to line, inverted ×6, double-spun per lab policy, frozen aliquot to coagulation lab. Patient 8 weeks post-DVT treatment; apixaban held 48 h per haematology. No acute leg pain today. Requisition notes family history of AT deficiency. Pending result; patient taught repeat test may be needed.”
- Indication, order date, and thrombophilia protocol timing met (yes/no)
- Tube type, fill level, mixing, processing, and transport compliance
- Recent VTE, pregnancy, liver/renal disease, and anticoagulant holds
- Result value with laboratory reference interval and flag status
- Prescriber/haematology notification and patient teaching provided
- Repeat specimen plan and genetics referral if ordered
Patient and Family Education
Patients often worry that a blood test predicts an immediate clot. Use clear, calm language about what antithrombin measures and why timing matters.
Antithrombin III NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Antithrombin III safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Antithrombin activity — plasma, thrombophilia panel
- Indication: 28-year-old with prior unprovoked DVT; family history of antithrombin deficiency
- Timing: Ordered today — 10 weeks after completing initial anticoagulation per protocol
- Related orders: Protein C, protein S, lupus anticoagulant screen; consider factor V Leiden per protocol
- Result: Antithrombin activity 62% (below laboratory reference); prior draw during acute DVT was 48%
- Trend / prior value: Improved from acute phase but still below reference; antigen assay pending
- Pending tests: Antithrombin antigen, genetics referral discussion, repeat activity in 6 weeks if on hold completed
- Vital signs: HR 78/min, BP 118/72, RR 16/min, SpO₂ 98% on room air, temp 36.9°C
- Symptoms: No current leg pain or dyspnoea; mild anxiety about “blood clot gene”
- Focused assessment: Calves symmetric, no tenderness; lungs clear; apixaban held 72 h per haematology order
- Preparation notes: Citrated tube filled to line; patient asked why test was not done during hospital admission
- Collection events: Previous sample rejected for underfilled citrate tube; today’s specimen accepted
- Teaching gaps / safety concerns: Low activity not yet confirmed hereditary; patient unclear on when to report symptoms; pending antigen
Answer key & rationale
Frequently Asked Questions
FAQ
Why is antithrombin tested after a blood clot instead of during the acute admission?
Acute thrombosis consumes antithrombin and anticoagulant therapy interferes with assays. clinical laboratory references recommends testing preferably a couple of months after a thrombotic episode and not while taking anticoagulants, or at least six weeks after stopping them — follow local policy.
Does the patient need to fast before antithrombin testing?
No test preparation is usually required per clinical laboratory references. Follow fasting instructions only if other ordered tests on the same draw require it.
What does a low antithrombin activity result mean?
It suggests reduced functional antithrombin, which may reflect inherited Type I or II deficiency or acquired causes such as liver disease, nephrotic syndrome, DIC, or recent thrombosis. Antigen testing and repeat sampling help clarify. It does not by itself prove an active clot today.
Can nurses draw antithrombin from a heparinized arterial or central line?
Avoid contamination when institutional policy requires clean peripheral draws. Heparin in the sample can invalidate coagulation results. Clarify line flushes and hold procedures with the lab and prescriber before collection.
Is antithrombin testing recommended for every patient with one DVT?
Not routinely. ASH 2023 guidelines conditionally recommend against broad thrombophilia testing in many VTE scenarios and support selective testing when results would change management — such as strong family history of antithrombin deficiency.
What tube is used for antithrombin activity?
Platelet-poor plasma from a light-blue-top tube with 3.2% sodium citrate, filled to the marked line, with gentle mixing and laboratory processing per coagulation protocol (often double-centrifuged and frozen for send-out testing).
When should nurses escalate before the result returns?
Escalate according to facility policy if the patient develops new unilateral leg swelling, pain, warmth, redness, chest pain, dyspnoea, tachycardia, or hypoxia — these may indicate acute VTE regardless of pending antithrombin results.
References
References
-
Association for Clinical Biochemistry and Laboratory Medicine. Antithrombin. Lab Tests Online UK.https://labtestsonline.org.uk/tests/antithrombin
-
Labcorp. Antithrombin (AT) Activity — Test 015040. Burlington (NC): Labcorp.https://www.labcorp.com/tests/015040/antithrombin-at-activity
-
Mayo Clinic Laboratories. Antithrombin Activity, Plasma (ATTF). Rochester (MN): Mayo Clinic.https://www.mayocliniclabs.com/test-catalog/Overview/800330
-
Kumar DR; et al. Biochemistry, Antithrombin III. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.https://www.ncbi.nlm.nih.gov/books/NBK545295/
-
Kujovich JL. Hypercoagulability. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.https://www.ncbi.nlm.nih.gov/books/NBK538251/
-
American Society of Hematology. 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023.https://pmc.ncbi.nlm.nih.gov/articles/PMC10709681/
-
Ng D; et al. Recommendations for clinical laboratory testing for antithrombin deficiency. J Thromb Haemost. 2020; SSC of the ISTH.https://pubmed.ncbi.nlm.nih.gov/31894660/
-
Stevens SM; et al. Hypercoagulable states: an algorithmic approach to laboratory testing. Blood Rev. 2016.https://pmc.ncbi.nlm.nih.gov/articles/PMC4090343/
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Antithrombin III.
Policies: Medical Review Process · Editorial Policy · Correction Policy